News 15.03.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial...
News 13.03.2024 Zürich, March 13, 2024 InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery. The study, in collaboration with PharmaNest, fills an existing gap, by developing and demonstrating a novel method for phenotypic quantification of fibrosis, using the...
News 13.03.2024 Schlieren (Zurich), Switzerland, March 13, 2024 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next-generation bone graft technologies, today announced financial results for full year 2023 along with continued significant growth. Direct sales of MagnetOs rose 163% to CHF 31.7 million in 2023 from CHF 12.1 million in 2022. Total...
News 06.03.2024 Lisbon, Portugal - 06.03.2024 Neurimmune announced today that a Donald L. Price Memorial Lecture will be held at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD 2024, in Lisbon, Portugal and virtually from March 5 to March 9, 2024. Professor Michel Goedert, Program Leader at the...
News 28.02.2024 (BOSTON: February 27, 2024) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding US$2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections. LimmaTech is a Swiss clinical stage biotech company that has built a robust pipeline of innovative vaccines to...